

Understanding Your Moderate Risk TP53 Genetic Test Result Information for patients with a moderate risk pathogenic or likely pathogenic variant

3 Things To Know

1	Result	Your testing shows that you have a moderate risk pathogenic or likely pathogenic (P/LP) variant in the <i>TP53</i> gene. Moderate risk variants may increase cancer risks, but less than typical variants do.
2	Reason for <i>TP53</i> moderate risk P/LP variant	 A TP53 moderate risk P/LP variant may already be in a person's body at birth (germline), or may have occurred at some point during a person's lifetime (somatic). People with a germline TP53 moderate risk P/LP variant may have attenuated Li Fraumeni syndrome or an increased risk for TP53-related cancers. The attenuated form of Li Fraumeni syndrome means that the risk of cancer may not be as high as in classic Li Fraumeni syndrome. People with a somatic TP53 moderate risk P/LP variant do NOT have Li Fraumeni syndrome or attenuated Li Fraumeni syndrome.
3	What this means for you	It is important to discuss your result in detail with your healthcare provider. Your report will indicate whether your <i>TP53</i> moderate risk P/LP variant may have occurred during your lifetime (somatic) or if your result is consistent with a diagnosis of attenuated Li Fraumeni syndrome: - If your report has a COMMENT about the possibility of somatic origin, see "Moderate Risk P/LP Variants of Unknown Origin in the <i>TP53</i> Gene" table below OR - If your report states you have a <i>TP53</i> moderate risk pathogenic or likely pathogenic variant with an increased risk for <i>TP53</i> -related cancers, see "Attenuated Li Fraumeni syndrome" table on page 2

Moderate Risk P/LP Variants of Unknown Origin in the <i>TP53</i> Gene Your test report includes a COMMENT about the possibility of somatic origin					
	 Sometimes TP53 moderate risk P/LP variants occur naturally in a person's blood later in life. These types of genetic changes can be observed even in healthy people, especially when they are over 65 years of age. 				
Desuit	 Somatic TP53 moderate risk P/LP variants can also be seen in blood as a result of chemotherapy or radiation treatments. 				
Result	 If your TP53 moderate risk P/LP variant is somatic, you do not have the same cancer risks associated with Li Fraumeni syndrome. It is important to discuss your specific management with your healthcare provider. 				
	 It is not always possible to distinguish definitively between germline and somatic variants. It is important to discuss next steps with your healthcare provider and decide on a plan that works for you. 				
Other Medical Concerns	Somatic <i>TP53</i> moderate risk P/LP variants are often detected in healthy people. However, some people with <i>TP53</i> moderate risk P/LP variants in blood may be at an increased risk for heart disease or blood cancers. It is important to discuss your management and screening options with your healthcare provider.				
Family	Testing your siblings, parents, and/or children can help determine if your <i>TP53</i> moderate risk P/LP variant is germline or somatic. If it is somatic, then neither you nor your family are at increased risk for the types of cancers that are seen more often in people with attenuated Li Fraumeni syndrome.				


Attenuated Li Fraumeni Syndrome

Your test report states that the result is consistent with attenuated Li Fraumeni syndrome (LFS), which is caused by permline *TP*53 moderate risk P/LP variants

germine 11 55 moderate	milline // 55 moderate fisk i / Er variants			
Attenuated Li Fraumeni syndrome	People with germline <i>TP53</i> moderate risk P/LP variants are more likely to have attenuated Li Fraumeni syndrome (LFS). The attenuated form of LFS means that the risk of cancer may not be as high as in classic LFS.			
Cancer Risk	People with classic LFS due to germline <i>TP53</i> P/LP variants have an increased chance to develop adrenocortical carcinoma (ACC) [†] , female** breast cancer, brain tumors, choroid plexus carcinoma [†] , leukemia, medulloblastoma [†] , osteosarcoma, rhabdomyosarcoma [†] , soft tissue sarcoma, and potentially other types of cancer. The lifetime risk for cancer may be as high as 90% [†] for females** or 70% for males**. Cancer risks can vary widely, even within the same family. If you have a moderate risk P/LP variant, the risks for cancer may not be as high as in classic LFS.			
Risk Management	Risk management decisions are very personal. There are options to detect cancer early or lower the risk to develop cancer. It is important to discuss these options with your healthcare provider and decide on a plan that works for you.			
Family	Up to 20% of the time, a person is born with a <i>TP53</i> variant that was not inherited from either parent. Testing family members for the P/LP <i>TP53</i> variant found in you could help to determine who in your family may or may not be at increased risk. It is recommended that you share this information with your family members so they can learn more and discuss with their healthcare providers.			


- These cancers are often diagnosed in childhood (<15 years).
- (Cumulative risk by age 60 years.

Cancer Risks Associated with Classic LFS[^]



Germline TP53 Variants in the Family^^

There is up to a 50/50 random chance to pass on a germline P/LP TP53 variant to each of your children.



- Colon cancer risk estimates are 20% or higher.
- Refers to sex assigned at birth
 Cancer risks associated with attenuated LFS may be lower than in classic LFS, but are not currently well defined
- People with somatic TP53 moderate risk P/LP variants cannot pass them on to their children.

RESOURCES

- FORCE facingourrisk.org
- Li-Fraumeni Syndrome Association Ifsassociation.org
- Living LFS livinglfs.blogspot.com
- National Society of Genetic Counselors nsgc.org
- Canadian Association of Genetic Counsellors cagc-accg.ca

Please discuss this information with your healthcare provider. The cancer genetics field is continuously evolving, so updates related to your TP53 result, medical recommendations, and/or potential treatments may be available over time. This information is not meant to replace a discussion with a healthcare provider, and should not be considered or interpreted as medical advice.

Clinician Management Resource for TP53

This overview of clinical management guidelines is based on this patient's positive test result for a moderate risk pathogenic or likely pathogenic variant in the *TP53* gene. Unless otherwise stated, medical management guidelines used here are limited to those issued by the National Comprehensive Cancer Network® (NCCN®)¹ in the U.S. Please consult the referenced guideline for complete details and further information.

Clinical correlation with the patient's past medical history, treatments, surgeries and family history may lead to changes in clinical management decisions; therefore, other management recommendations may be considered. Genetic testing results and medical society guidelines help inform medical management decisions but do not constitute formal recommendations. Discussions of medical management decisions and individualized treatment plans should be made in consultation between each patient and his or her healthcare provider, and may change over time.

NOTE:

- If the patient's report has a COMMENT about the possibility of acquired (somatic) origin, refer to the "Moderate Risk P/LP Variants of Unknown Origin in the TP53 Gene" table below for management guidelines. See the NCCN Guidelines pages LIFR-A 1 through 3 for a more detailed discussion of causes and management of atypical TP53 findings.
- If the patient's report states that the *TP53* Moderate Risk pathogenic or likely pathogenic variant is consistent with attenuated Li Fraumeni syndrome, refer to the "Attenuated Li Fraumeni syndrome" table on the next page for management guidelines.

Moderate Risk P/LP Variants of Unknown Origin in the TP53 Gene The patient's test report includes a COMMENT about the possibility of somatic origin					
Clinical correlation	 TP53 variants found in blood, saliva, or buccal samples may be present from birth (germline) or acquired later in life (somatic). Your patient's test report will indicate if the identified TP53 variant is of uncertain origin It is not always possible to distinguish definitively between germline and acquired (somatic) variants. Clinical presentation may help guide management of these patients. 				
Reasons for somatic <i>TP53</i> moderate risk variants identified in blood or saliva	Aberrant clonal expansion (ACE) due to clonal hematopoiesis (CHiP) • Common in healthy older age populations (over 65 years) Chemotherapy treatment Radiation treatment				
Management and Next Steps	 Management of individuals with identified TP53 moderate risk variants will differ markedly depending on if the TP53 variant is germline or acquired (somatic). Testing of family members (such as siblings, parents, and/or children) can help distinguish between germline and acquired (somatic) variants, although it is not always possible to do so.^{1,2} Acquired (somatic) TP53 variants: these individuals do not have Li Fraumeni syndrome (LFS) and are not at increased risk for LFS cancers. Management is based on personal and family history. These individuals may be at risk for heart disease or blood cancers.¹ Careful examination of the patient's complete blood count (CBC) and peripheral blood smear may be warranted in all individuals with identified TP53 pathogenic or likely pathogenic variants and testing of non-hematopoietic tissue(s) may help confirm true mosaic involvement across different germ layers.^{1,2} 				

- 1. Weitzel J, et al. *Genet Med* 2018;20:809 816.
- Chao E, et al. Genet Med 2021 Jul;23(7):1179 1184.

Attenuated Li Fraumeni Syndrome
The patient's test report states that the result is consistent with attenuated Li Fraumeni syndrome (LFS), which is caused by germline moderate risk pathogenic or likely pathogenic variants in the *TP53* gene

Personal Description	SCREENING/SURC	GICAL CONSIDERATIONS ¹	AGE TO START	FREQUENCY		
Women should be familiar with their breasts and promptly report changes to their healthcare provider p	Female Breast Can	cer				
And promptly report changes to their healthcare provider Clinical Breast Exam Breast MRI with and without contrast Breast MRI with and without contrast and mammogram Breast MRI with and without contrast and mammogram Breast MRI with and without contrast and mammogram Discuss option of risk-reducing mastectomy Individualized Discuss option of risk-reducing mastectomy Individualized Every 12 months Every 12 months Every 2-15 years Colorectal and Intestinal Cancer Colonescopy and upper endoscopy Colonescopy and upper endoscopy Colonescopy and upper endoscopy Colonescopy and upper endoscopy Propatients who have received whole body or abdominal therapeutic radiation treatment, colon or gastric cancer in the family (whichever comes first) For patients who have received whole body or abdominal therapeutic radiation treatment, colonescopy screening is recommended Dermatologic exam Dermatologic exam 18 years old Every 12 months Every 12 months (with consider parceratic cancer diagnosis in the family as the identified pathogenic/likely pathogenic permitine variant, consider parceratic and family and pathogenic permitine variant, consider parceratic and	Breast Awareness					
Breast MRI with and without contrast 20-29 years old for at the age of earliest diagnosed breast cancer in the family), whichever comes first 20-29 years old for at the age of earliest diagnosed breast cancer in the family), whichever comes first, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy 30-75 years old 30-	and promptly report changes to their healthcare		18 years old	Periodic and consistent		
Breast Screening	Clinical Breast Exam		breast cancer in the family), whichever comes	Every 6-12 months		
Breast MRI with and without contrast and mammogram breast cancer and who have not had bilateral mastectomy Discuss option of risk-reducing mastectomy Individualized N/A Brain Tumors Brain MRI as part of whole body MRI (see below, Other Cancers), or a separate exam Individualized Every 12 months Permatogic exam* Colonoscopy and upper endoscopy Colonoscopy and upper endoscopy Colonoscopy and upper endoscopy Sparatine and intestinal Cancer Colonoscopy and upper endoscopy Colonoscopy screening is recommended Belanoma Dermatologic exam 18 years old, or 5 years before earliest known colon or gastric cancer in the family (whichever comes first) Sparatine and interapeutic radiation treatment, colonoscopy screening is recommended Belanoma Dermatologic exam 18 years old Every 12 months Every 12 months Every 12 months Every 12 months Sol years (or 10 years younger than the earliest exocrine pancreatic cancer in family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic ancer screening using contrast-enhanced MRI/MRCP and/or EUS.* Prostate Cancer Prostate Cancer Prostate Cancer Prostate Sparatic examination with high index of suspicion for rare cancers and second malignancies in cancer and who have not had bilateral mastectomy Individualized Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Infancy Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Infancy Every 6-12 months Every 6-12 months			diagnosed breast cancer in the family), whichever comes first, including women treated for breast cancer and who have not had bilateral	Individualized after 75		
Brain Tumors Brain MRI as part of whole body MRI (see below, Other Cancers), or a separate exam Individualized Every 12 months Every 6-12 months Colorectal and Intestinal Cancer Colonoscopy and upper endoscopy Colonoscopy and endoscopy Colonoscopy and endo			breast cancer and who have not had bilateral			
Brain MRI as part of whole body MRI (see below, Other Cancers), or a separate exam	Discuss option of ri	sk-reducing mastectomy	Individualized	N/A		
Neurologic exam** Individualized Every 6-12 months Colorectal and Intestinal Cancer Colonoscopy and upper endoscopy Colonoscopy and upper endoscopy 25 years old, or 5 years before earliest known colon or gastric cancer in the family (whichever comes first) For patients who have received whole body or abdominal therapeutic radiation treatment, colonoscopy screening is recommended Melanoma Dermatologic exam 18 years old Every 12 months Every 2-5 years Every 2-5 years Colonoscopy screening is recommended Melanoma Dermatologic exam 18 years old Every 12 months Every 12 months Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening using contrast-enhanced MRI/ MRCP and/or EUS.^* Prostate Cancer Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Infancy Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Prostate Cancer Frostate-specific antigen (PSA) testing Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam.	Brain Tumors					
Colonectal and Intestinal Cancer Colonoscopy and upper endoscopy Colonoscopy and upper endoscopy Comparison who have received whole body or abdominal therapeutic radiation treatment, colonoscopy screening is recommended Melanoma Dermatologic exam Dermatologic exam 18 years old Every 2-5 years Every 12 months Pancreatic Cancer For individuals with exocrine pancreatic cancer in Pancreatic defined pathogenic/likely pathogenic germline variant, consider pancreatic exacer of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic exocrine pancreatic cancer diagnosis in the family) Prostate Cancer Prostate Cancer Prostate - specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 12 months Every 12 months Every 6-12 months Every 6-12 months			Individualized	Every 12 months		
Colonoscopy and upper endoscopy 25 years old, or 5 years before earliest known colon or gastric cancer in the family (whichever comes first) For patients who have received whole body or abdominal therapeutic radiation treatment, colonoscopy screening is recommended Melanoma Dermatologic exam 18 years old Every 12 months Pancreatic Cancer For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/ MRCP and/or EUS.⁴ Prostate Cancer Prostate Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (malignancies in cancer survivors Infancy Every 6-12 months Every 6-12 months	Neurologic exam**		Individualized	Every 6-12 months		
Colonoscopy and upper endoscopy colon or gastric cancer in the family (whichever comes first) Every 2-5 years For patients who have received whole body or abdominal therapeutic radiation treatment, colonoscopy screening is recommended 5 years after treatment of disease Every 2-5 years Melanoma It years old Every 12 months Dermatologic exam 18 years old Every 12 months Pancreatic Cancer For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer diagnosis in the family) 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Infancy Every 6-12 months Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 12 months	Colorectal and Inte	stinal Cancer				
or abdominal therapeutic radiation treatment, colonoscopy screening is recommended Melanoma Dermatologic exam 18 years old Every 12 months Pancreatic Cancer For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/MRCP and/or EUS.^ Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 12 months Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months Every 6-12 months	Colonoscopy and u	pper endoscopy	colon or gastric cancer in the family (whichever	Every 2-5 years		
Dermatologic exam Pancreatic Cancer For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/ MRCP and/or EUS.^ Prostate Cancer Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Is years old Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months Every 6-12 months	or abdominal thera	peutic radiation treatment,	5 years after treatment of disease	Every 2-5 years		
Pancreatic Cancer For individuals with exocrine pancreatic cancer in 21 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer diagnosis in the family) For individuals with exocrine pancreatic cancer in 21 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer diagnosis in the family) For state Cancer Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family)	Melanoma					
For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/ MRCP and/or EUS.^ Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening) Every 12 months Every 6-12 months Every 12 months	Dermatologic exam	1	18 years old	Every 12 months		
≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/MRCP and/or EUS.^ Prostate Cancer Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family) For the exocrine pancreatic cancer diagnosis in the family) Infancy Fivery 12 months (With consideration of shorter intervals if worrisome abnormalities seen on screening) Fivery 12 months (With consideration of shorter intervals if worrisome abnormalities seen on screening) Fivery 12 months (With consideration of shorter intervals if worrisome abnormalities seen on screening)	Pancreatic Cancer					
Prostate-specific antigen (PSA) testing 40 years old Individualized Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Infancy Every 6-12 months	≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/		exocrine pancreatic cancer diagnosis in the	consideration of shorter intervals if worrisome abnormalities seen on		
Pediatric Surveillance Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 6-12 months Every 12 months	Prostate Cancer	Prostate Cancer				
Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 6-12 months Every 12 months	Prostate-specific a	ntigen (PSA) testing	40 years old	Individualized		
examination with high index of suspicion for rare cancers and second malignancies in cancer survivors Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam. Infancy Every 6-12 months Every 12 months	Pediatric Surveillance					
part of the whole body MRI or as a separate exam.	examination with high index of suspicion for rare cancers and second malignancies in cancer		Infancy	Every 6-12 months		
Ultrasound for adrenocortical carcinoma Infancy Every 3-4 months			Infancy	Every 12 months		
	Ultrasound for adre	enocortical carcinoma	Infancy	Every 3-4 months		

Other Aspects of Managing LFS			
The screening and management of LFS is complex and LFS is rare; it is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome.	N/A	N/A	
Address limitations of screening for many cancers associated with Li-Fraumeni syndrome (LFS). Screening should be considered for cancer survivors with LFS and a good prognosis from their prior tumor(s).	N/A	N/A	
Screening recommendations should take into account personal and family history of cancer. Provide additional surveillance based on family history of cancer.	5-10 years before the earliest diagnosis	Individualized	
Therapeutic radiation treatment for cancer should be avoided when possible unless locoregional risk reduction or overall survival from radiation treatment is greater than the risk of downstream secondary malignancies; diagnostic radiation should be minimized to the extent feasible without sacrificing accuracy.	N/A	N/A	
Provide education regarding signs and symptoms of cancer.	N/A	N/A	
Address psychosocial and quality-of-life aspects of management	N/A	N/A	

- ** This may be done as part of the comprehensive physical exam
- † While there are no specific management recommendations for individuals with a moderate risk pathogenic or likely pathogenic variant, a cautious approach would be to follow the same management guidelines as for individuals with a typical *TP53* pathogenic or likely pathogenic variant. NCCN guidelines do not specify management for individuals with a moderate risk pathogenic or likely pathogenic variant.
- A For individuals considering pancreatic cancer screening, the Guidelines recommends that screening be performed in experienced high-volume centers. The Guidelines recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or intermediate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The Guidelines recommends that screening be considered using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals for individuals found to have worrisome abnormalities on screening. The Guidelines emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and
 Prostate. v2.2025. ® National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 7, 2024. To view the most recent and complete version of the
 guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use
 in any way.
- 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. v3.2024.® National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed October 31, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for